UK Minimally Invasive Surgery Devices Market

ID: MRFR/HC/48806-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026
UK Minimally Invasive Surgery Devices Market Research Report By Application (General Surgery, Cardiothoracic Surgery, Gynecological Surgery, Urological Surgery, Orthopedic Surgery), By Product Type (Endoscopes, Robotic Surgery Systems, Laparoscopic Surgical Instruments, Visualization Systems, Access Devices), By End Use (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) and By Technology (Video-Assisted Thoracoscopic Surgery, Transcatheter Aortic Valve Replacement, Natural Orifice Transluminal Endoscopic Surgery) -Forecast to 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Minimally Invasive Surgery Devices Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)9.2%
2024 Market Size$ 690.93 Million
2025 Market Size$ 754.5 Million
2035 Market Size$ 1,820 Million

Key Players

Medtronic
Johnson & Johnson
Boston Scientific
Stryker
Abbott Laboratories
B. Braun Melsungen AG
Opportunities
  • Aging Population and Increased Surgical Needs
  • Technological Innovations in Surgical Devices
  • Increased Focus on Patient Safety and Outcomes
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Application (USD Million)
      1. 4.1.1 General Surgery
      2. 4.1.2 Cardiothoracic Surgery
      3. 4.1.3 Gynecological Surgery
      4. 4.1.4 Urological Surgery
      5. 4.1.5 Orthopedic Surgery
    2. 4.2 Pharmaceutical, BY Product Type (USD Million)
      1. 4.2.1 Endoscopes
      2. 4.2.2 Robotic Surgery Systems
      3. 4.2.3 Laparoscopic Surgical Instruments
      4. 4.2.4 Visualization Systems
      5. 4.2.5 Access Devices
    3. 4.3 Pharmaceutical, BY End-use (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Ambulatory Surgical Centers
      3. 4.3.3 Specialty Clinics
    4. 4.4 Pharmaceutical, BY Technology (USD Million)
      1. 4.4.1 Video-Assisted Thoracoscopic Surgery
      2. 4.4.2 Transcatheter Aortic Valve Replacement
      3. 4.4.3 Natural Orifice Transluminal Endoscopic Surgery
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Medtronic (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Johnson & Johnson (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Boston Scientific (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Stryker (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Abbott Laboratories (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 B. Braun Melsungen AG (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Olympus Corporation (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Smith & Nephew (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Intuitive Surgical (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY APPLICATION
    3. 6.3 UK MARKET ANALYSIS BY PRODUCT TYPE
    4. 6.4 UK MARKET ANALYSIS BY END-USE
    5. 6.5 UK MARKET ANALYSIS BY TECHNOLOGY
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY END-USE, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY END-USE, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY END-USE, 2025-2035 (USD Million)
      4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Pharmaceutical Market Segmentation

Pharmaceutical By Application (USD Million, 2025-2035)

  • General Surgery
  • Cardiothoracic Surgery
  • Gynecological Surgery
  • Urological Surgery
  • Orthopedic Surgery

Pharmaceutical By Product Type (USD Million, 2025-2035)

  • Endoscopes
  • Robotic Surgery Systems
  • Laparoscopic Surgical Instruments
  • Visualization Systems
  • Access Devices

Pharmaceutical By End-use (USD Million, 2025-2035)

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

Pharmaceutical By Technology (USD Million, 2025-2035)

  • Video-Assisted Thoracoscopic Surgery
  • Transcatheter Aortic Valve Replacement
  • Natural Orifice Transluminal Endoscopic Surgery